2. Search Result
Search Result
Pathways Recommended: Cell Cycle/DNA Damage
Results for "

cisplatin damage

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Peptides

4

Natural
Products

2

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0019C
    (R)-Azasetron besylate

    SENS-401

    		 Phosphatase Cancer
    (R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage .
    (R)-Azasetron besylate
  • HY-13700
    Nedaplatin
    1 Publications Verification

    NSC 375101D

    		 DNA/RNA Synthesis Cancer
    Nedaplatin (NSC 375101D) is a derivative of cisplatin and DNA damage agent.
    Nedaplatin
  • HY-17394
    Cisplatin
    Maximum Cited Publications
    602 Publications Verification

    cis-Platinum; CDDP; cis-Diaminodichloroplatinum

    		 DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Lipoxygenase Cancer
    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    Cisplatin
  • HY-44307
    84-B10

    		Ferroptosis Cancer
    84-B10 is a 3-phenylglutaric acid derivative. 84-B10 inhibits cisplatin (HY-17394) induced tubular ferroptosis. 84-B10 attenuates cisplatin-induced mitochondrial damage and oxidative stress. 84-B10 ameliorates cisplatin-induced acute kidney injury (AKI) .
    84-B10
  • HY-N7046
    Silybin B

    Silibinin B

    		 Amyloid-β Apoptosis JNK p38 MAPK Neurological Disease Cancer
    Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B
  • HY-156368
    RIPK3-IN-4

    		RIP kinase Inflammation/Immunology
    RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor. RIPK3-IN-4 inhibits HK-2 cell damage, necroptosis and inflammatory responses. RIPK3-IN-4 reduces Cisplatin (HY-17394)- and I/R-induced kidney damage, inflammatory response and necroptosis in acute kidney injury .
    RIPK3-IN-4
  • HY-117846
    MLAF50

    		DNA/RNA Synthesis Cancer
    MLAF50 is apotent REV1 UBM2-Ubiquitin interaction inhibitor. MLAF50 inhibits chromatin co-localization of REV1 with PCNA following DNA-damage induction .
    MLAF50
  • HY-163506
    Ebselen derivative 1

    		Apoptosis Ferroptosis Others
    Ebselen derivative 1 (Compound 19) is a glutathione peroxidase (GPx) mimic with oral activity. Ebselen derivative 1 demonstrates significant protective effects against cisplatin (HY-17394)-induced hair cell (HC) damage both in vitro and in vivo, effectively reducing oxidative stress, apoptosis, and ferroptosis in hair cells. Ebselen derivative 1 can be utilized in the research of cisplatin (HY-17394)-induced hearing loss .
    Ebselen derivative 1
  • HY-176238
    CX116

    		Apoptosis Metabolic Disease Cancer
    CX116 is an orally active anti-inflammatory agent. CX116 exerts its effects by inhibiting the inflammatory response, reducing oxidative stress, protecting mitochondrial function, and counteracting apoptosis. CX116 bears acceptable toxicity and appropriate pharmacokinetic properties, and can significantly protect renal tissue from Cisplatin (HY-17394)-induced damage. CX116 can be used for the study of Cisplatin-induced acute kidney injury (cis-AKI) .
    CX116
  • HY-146194
    NHEJ inhibitor-1

    		Reactive Oxygen Species (ROS) Cancer
    NHEJ inhibitor-1 (Compound C2) is a trifunctional Pt(II) complex, alleviates the non-homologous end connection (NHEJ)/homologous recombination (HR)-related double strand breaks (DSBs) repairs to evade Cisplatin-resistance in non-small cell lung cancer (NSCLC). NHEJ inhibitor-1 inhibits the damage repair proteins Ku70 and Rad51 to make tumors re-sensitive to Cisplatin. NHEJ inhibitor-1 also induces ROS generation and MMP deduction .
    NHEJ inhibitor-1
  • HY-D2438
    CDDP-PEG-Cy3

    		Fluorescent Dye Cancer
    CDDP-PEG-Cy3 is a CDDP-PEG conjugate labeled with Cy3 (HY-D0822). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Cisplatin (CDDP) (HY-17394) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy .
    CDDP-PEG-Cy3
  • HY-P10243
    Ac-VAD-CMK

    		Caspase Neurological Disease
    Ac-VAD-CMK is a pan inhibitor for caspase 1 .
    Ac-VAD-CMK
  • HY-N7046S
    Silybin B-d3

    Silibinin B-d3

    		 Isotope-Labeled Compounds Amyloid-β Apoptosis JNK p38 MAPK Neurological Disease Cancer
    Silybin B-d3 (Silibinin B-d3) is a deuterated Silybin B (HY-N7046). Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B-d3
  • HY-N7046R
    Silybin B (Standard)

    Silibinin B (Standard)

    		 Reference Standards JNK Amyloid-β p38 MAPK Apoptosis Neurological Disease Cancer
    Silybin (Silibinin B) (Standard) is the analytical standard of Silybin B (HY-N7046). This product is intended for research and analytical applications. Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394)-induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity .
    Silybin B (Standard)
  • HY-139038
    TDRL-X80

    		DNA/RNA Synthesis Cancer
    TDRL-X80 is a potent inhibitor of xeroderma pigmentosum group A (XPA) protein. TDRL-X80 inhibits XPA’s DNA binding activity. TDRL-X80 exhibits activity against single, double, and Cisplatin-damaged DNA with IC50s of 18, 20, and 29 μM in fluorescence polarization (FP) analyses , and with IC50s of 21, 39, and 28 in ELISA Analysis .
    TDRL-X80
  • HY-161647
    Antitumor agent-156

    		Reactive Oxygen Species (ROS) Apoptosis Autophagy Ferroptosis Cancer
    Antitumor agent-156 (Compound 20) causes DNA damage and mitochondrial dysfunction, promotes reactive oxygen species generation, activates endoplasmic reticulum stress, and induce apoptosis, autophagy and ferroptosis. Antitumor agent-156 shows superior antitumor activity against cancer cells including Cisplatin (HY-17394) resistance cells. Antitumor agent-156 displayS good liver-targeting ability .
    Antitumor agent-156
  • HY-B1398
    Ampyrone
    1 Publications Verification

    4-Aminophenazone

    		 COX Drug Metabolite Neurological Disease Inflammation/Immunology Cancer
    Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
    Ampyrone
  • HY-W127709
    Chlorophyll b

    		Biochemical Assay Reagents Glutathione Peroxidase Others
    Chlorophyll b is an orally active tetrapyrrole derivative and pigment. Chlorophyll b can be obtained from photosynthetic organisms such as plants and algae. Chlorophyll b acts as a hydrogen donor and increases Glutathione levels. Chlorophyll b has antioxidant activity and functionally replaces chlorophyll a in photosystem II to participate in photosynthesis. Chlorophyll b reduces Cisplatin (HY-17394)-induced DNA damage, chromosome instability, and oxidative stress. Chlorophyll b is mainly used in the study of plant photosynthesis mechanism .
    Chlorophyll b
  • HY-13981
    Ligandrol
    2 Publications Verification

    LGD-4033

    		 Androgen Receptor Apoptosis Insulin Receptor Caspase Metabolic Disease Endocrinology
    Ligandrol is an orally active, selective androgen receptor (AR) agonist. Ligandrol enhances protein synthesis, inhibits muscle breakdown and oxidative stress, improves muscle cell viability and bone tissue microstructure, and reduces Cisplatin (HY-17394)-induced muscle toxicity and apoptosis. Ligandrol promotes muscle growth, protects bone structure, and has anti-diabetic, anti-apoptotic and antioxidant effects. Ligandrol can antagonize Streptozotocin (HY-13753) damage to pancreatic islets and improve the symptoms of type 2 diabetes .
    Ligandrol
  • HY-124691
    D-I03
    3 Publications Verification

    		 DNA/RNA Synthesis Cancer
    D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 μM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 μM and 8 μM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin .
    D-I03
  • HY-142956
    ROS-ERS inducer 1

    		Reactive Oxygen Species (ROS) Cancer
    ROS-ERS inducer 1 is a type II ICD (immunogenic cell death) inducer. ROS-ERS inducer 1 is a Pt(II)-N-heterocyclic carbene (Pt(II)-NHC) complex derived from 4,5-diarylimidazole. ROS-ERS inducer 1 successfully induces endoplasmic reticulum stress (ERS) accompanied by reactive oxygen species (ROS) generation and finally lead to the release of damage-associated molecular patterns (DAMPs) in HCC cells. ROS-ERS inducer 1 displays much higher anticancer activities than Cisplatin .
    ROS-ERS inducer 1
  • HY-B1398S
    Ampyrone-d3

    4-Aminoantipyrine-d3

    		 Isotope-Labeled Compounds COX Drug Metabolite Neurological Disease Inflammation/Immunology Cancer
    Ampyrone-d3 is the deuterium labeled Ampyrone (HY-B1398). Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
    Ampyrone-d3
  • HY-154629
    Sesame Oil
    1 Publications Verification

    		 Biochemical Assay Reagents NF-κB Aminotransferases (Transaminases) Interleukin Related NO Synthase Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Sesame Oil is a vegetable oil. Sesame Oil can be extracted from the seeds of Sesamum indicum L. Sesame Oil decreases NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4 and nitric oxide. Sesame Oil has antitumor activity against malignant melanoma. Sesame Oil has protective effects against liver damage caused by various agents such as Cisplatin (HY-17394) and Acetaminophen (HY-66005). Sesame Oil shows antinociceptive and anti-inflammatory activities .
    Sesame Oil
  • HY-B1398R
    Ampyrone (Standard)
    1 Publications Verification

    4-Aminophenazone (Standard)

    		 Reference Standards COX Drug Metabolite Neurological Disease Inflammation/Immunology Cancer
    Ampyrone (4-Aminophenazone) (Standard) is the analytical standard of Ampyrone (HY-B1398). This product is intended for research and analytical applications. Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
    Ampyrone (Standard)
  • HY-155008
    PROTAC HK2 Degrader-1
    2 Publications Verification

    		 PROTACs Hexokinase Cancer
    PROTAC HK2 Degrader-1 is a PROTAC consisting of Lonidamine (HY-B0486) as a target protein Hexokinase 2 (HK2) inhibitor and Thalidomide (HY-14658) as a CRBN ligand-linked PROTAC. PROTAC HK2 Degrader-1 selectively inhibits the proliferation of breast cancer cells by forming a ternary complex through the ubiquitin-proteasome system to degrade Hexokinase 2 (HK2) protein leading to mitochondrial damage and cell death. PROTAC HK2 Degrader-1 effectively inhibits breast tumor growth and reduces the colonic side effects of cisplatin for breast cancer research .
    PROTAC HK2 Degrader-1
  • HY-172201
    NF-κB-IN-19

    		NF-κB Reactive Oxygen Species (ROS) Autophagy Apoptosis HIF/HIF Prolyl-Hydroxylase Akt STAT PI3K Inflammation/Immunology Cancer
    NF-κB-IN-19 (Compound 8) is an NF-κB inhibitor. NF-κB-IN-19 effectively induces DNA damage, promotes the generation of ROS, and induces autophagy and apoptosis through the NF-κB signaling pathway in tumor cells. In addition, NF-κB-IN-19 can inhibit the levels of VEGF and HIF-1α, and exert antiproliferative activity in tumor cells through the PI3K/AKT and STAT-3 pathways. NF-κB-IN-19 can effectively overcome cisplatin resistance and has anti-tumor activity .
    NF-κB-IN-19
  • HY-173023
    IDOi-Pt(IV) prodrug-1

    		Apoptosis Indoleamine 2,3-Dioxygenase (IDO) Reactive Oxygen Species (ROS) Cancer
    IDOi-Pt(IV) prodrug-1 (Compound 10) is an IDOi-Pt(IV) prodrug. IDOi-Pt(IV) prodrug-1 inhibits IDO expression. IDOi-Pt(IV) prodrug-1 induces apoptosis, decreases the mitochondrial membrane potential, inhibits tumor cell migration and invasion. IDOi-Pt(IV) prodrug-1 induces reactive oxygen species-mediated endoplasmic reticulum stress and secretion of damage-associated molecular patterns (DAMPs), thereby presenting immunogenic cell death (ICD) effects. IDOi-Pt(IV) prodrug-1 has high-efficiency and low-toxicity antitumor effects compared to Cisplatin (HY-17394) .
    IDOi-Pt(IV) prodrug-1
  • HY-N0648
    Monotropein
    1 Publications Verification

    		 Interleukin Related Keap1-Nrf2 Heme Oxygenase (HO) NF-κB Apoptosis Inflammation/Immunology
    Monotropein is an iridoid glycoside that can be isolated from the roots of Morinda officinalis. Monotropein inhibits the expression of inflammatory mediators in dextran sulfate sodium (DSS)-induced colitis mouse model. Monotropein exerts protective effects against IL-1β-induced apoptosis and catabolic responses on osteoarthritis chondrocytes. Monotropein has cartilage protective activity. Monotropein can alleviate Cisplatin (HY-17394)-induced acute kidney injury by inhibiting oxidative damage, inflammation and apoptosis through activation of Nrf2/HO-1 pathway and inhibition of NF-κB signaling. Monotropein can be studied in research for osteoarthritis, acute kidney injury and acute lung injury .
    Monotropein
  • HY-158156
    NF-κB-IN-16

    		NF-κB Apoptosis Cancer
    NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .
    NF-κB-IN-16
  • HY-N0648R
    Monotropein (Standard)

    		Reference Standards Interleukin Related Heme Oxygenase (HO) Keap1-Nrf2 NF-κB Apoptosis Inflammation/Immunology
    Monotropein (Standard) is the analytical standard of Monotropein. This product is intended for research and analytical applications. Monotropein is an iridoid glycoside that can be isolated from the roots of Morinda officinalis. Monotropein inhibits the expression of inflammatory mediators in dextran sulfate sodium (DSS)-induced colitis mouse model. Monotropein exerts protective effects against IL-1β-induced apoptosis and catabolic responses on osteoarthritis chondrocytes. Monotropein has cartilage protective activity. Monotropein can alleviate Cisplatin (HY-17394)-induced acute kidney injury by inhibiting oxidative damage, inflammation and apoptosis through activation of Nrf2/HO-1 pathway and inhibition of NF-κB signaling. Monotropein can be studied in research for osteoarthritis, acute kidney injury and acute lung injury .
    Monotropein (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: